Labile iron affects pharmacological ascorbate-induced toxicity in osteosarcoma cell lines.

Area of Science:

• Biochemistry
• Cell Biology
• Oncology

Background:

• Vitamin C (ascorbate) and iron are essential nutrients involved in redox reactions.
• Vitamin C acts as an electron donor but can be pro-oxidant with catalytic iron.
• Cancer cells exhibit increased iron requirements compared to normal cells.

Purpose of the Study:

• To investigate the role of intracellular labile iron in mediating the anti-cancer effects of pharmacological ascorbate.
• To explore the mechanisms by which ascorbate and iron induce oxidative stress in cancer cells.
• To evaluate the potential of manipulating iron levels for enhanced cancer therapy.

Main Methods:

• Treatment of cancer cells with pharmacological ascorbate.
• Measurement of intracellular hydrogen peroxide (H2O2) levels.
• Assessment of the effects of varying iron concentrations (Fe3+, Fe2+) and chelators (DFO, BIP) on ascorbate-induced toxicity.
• Analysis of ferritin expression in response to ascorbate and iron.

Main Results:

• Pharmacological ascorbate significantly increased intracellular H2O2 levels.
• Intracellular labile iron potentiated ascorbate-induced oxidative stress via the Fenton reaction.
• Excess extracellular iron diminished ascorbate's toxicity, while intracellular iron enhanced it.
• Deferoxamine (DFO) showed a greater inhibitory effect on ascorbate toxicity than 2,2'-bipyridyl (BIP).

Conclusions:

• Intracellular iron enhances the selective toxicity of pharmacological ascorbate towards cancer cells.
• The differential effects of iron inside and outside cells highlight the importance of iron localization.
• Targeting iron metabolism in tumors could be a viable strategy to improve the efficacy of ascorbate-based cancer treatments.